Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal mRNA-1273 vaccination in adults with fibrodysplasia ossificans progressiva
NL-OMON51673Phase 2Recruiting
- Sponsor
- Nederlandse Federatie van Universitair Medische Centra
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Nederlandse Federatie van Universitair Medische Centra. Primary endpoints: Local reactogenicity, Systemic reactogenicity and safety and 1 more. Started Apr 2022; status: recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51673.